Sulforaphane Use to Effect Inflammatory and Metabolic Changes in Virally Suppressed HIV Patients

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05224492

Enrollment

Registered

2022-02-04

Start date

2022-02-21

Completion date

2022-09-21

Last updated

2022-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV Infections

Brief summary

Assess the effects of Sulforaphane supplementation in HIV patients that have achieved viral suppression.

Interventions

DRUGSulforaphane

40 mg of Sulforaphane powder once daily.

OTHERPlacebo

Placebo

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

18 Years to 85 Years

Healthy volunteers

Inclusion criteria

* HIV patients on active treatment who have a suppressed viral load and have been virally suppressed for 6 months or more. * BMI increase of 10% or more since initiation of HIV treatment over a year period. * BMI equal to or greater than 30. * 18-85 years of age.

Exclusion criteria

* Cancer * Pregnancy or breastfeeding * Intolerance to cruciferous vegetables * Intolerance to sulforaphane * Gluten Intolerance * Creatinine \> 1.3 mg/dL * GFR \< 60 * AST or ALT \> 1.5 times upper limit of normal. * White cell count \< 2000 cells per ml. * Hemoglobin \< 10.5 g/dL. * Platelet count \< 140,000 per ml.

Design outcomes

Primary

Measure	Time frame	Description
Lipids	4 months	Triglycerides, Cholesterol
Inflammatory Markers	4 months	CRP

Contacts

Primary ContactJohannah G Katz

Johannahfgiron@gmail.com4074894750

Backup ContactJose A. Giron, MD

Joseoidc@aol.com4078885980

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026